No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARMP Armata Pharmaceuticals
- 2.700
- -0.170-5.92%
Close Jun 14 16:00 ET
- 2.700
- 0.0000.00%
Post 16:00 ET
97.62MMarket Cap-1227P/E (TTM)
2.908High2.700Low10.25KVolume2.860Open2.870Pre Close28.69KTurnover0.09%Turnover RatioLossP/E (Static)36.15MShares5.25752wk High-1.73P/B29.74MFloat Cap1.07052wk Low--Dividend TTM11.02MShs Float392.000Historical High--Div YieldTTM7.26%Amplitude0.001Historical Low2.799Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
Armata Pharmaceuticals | 10-Q: Quarterly report
Express News | Armata Pharmaceuticals Inc: Qtrly Shr Loss $0.69
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
04:14 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
Comments
$Armata Pharmaceuticals(ARMP.US$ Armata has shown a rapid enrollment rate in the Phase 2a portion of the diSArm study, which tests AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Furthermore, the company is making strides in the Phase 2 Tailwind study of AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with Pseudomonas aeruginosa lung infections.
The second reason for is Armata’s diligence in preparing for future studies. The company i...
The second reason for is Armata’s diligence in preparing for future studies. The company i...
$AbbVie(ABBV.US$ $Align Technology(ALGN.US$ $Armata Pharmaceuticals(ARMP.US$ $Ault Alliance(AULT.US$ $Becton Dickinson & Co(BDX.US$ $Carmell(CTCX.US$ $Edwards Lifesciences(EW.US$ $National Vision(EYE.US$ $Icon PLC(ICLR.US$ $Lam Research(LRCX.US$ $Molina Healthcare(MOH.US$ $Impinj(PI.US$ $Rimini Street(RMNI.US$ $Silicon Motion Technology(SIMO.US$ $United Rentals(URI.US$ $Warrantee(WRNT.US$
2
$Armata Pharmaceuticals(ARMP.US$
$NN Inc(NNBR.US$ AH up 12% may look for lower entry or risk management will help
$NN Inc(NNBR.US$ AH up 12% may look for lower entry or risk management will help
3
5
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg